Feature Channels: Vaccines

• share
• favorite_border

Albert Einstein College of Medicine has received a five-year, $14 million per year grant from the National Institute of Allergy and Infectious Diseases (NIAID) to participate in a broad national effort to develop "plug-and-play" vaccines and antibody-based therapies against a wide range of emerging viruses. The grant is part of NIAID’s new Research and Development of Vaccines and Monoclonal Antibodies for Pandemic Preparedness (ReVAMPP) Network, which was announced earlier today.

• share
• favorite_border

With flu season just around the corner and COVID-19 cases on the rise, a new nationwide survey from The Ohio State University Wexner Medical Center reveals hesitancy around vaccines this fall. The new data comes just as this year’s flu shot rolls out and following the FDA’s approval of an updated round of COVID-19 vaccines.

• share
• favorite_border

La Jolla Institute for Immunology (LJI) has been selected as a spoke for the Investor Catalyst Hub, a regional hub of ARPANET-H, a nationwide health innovation network launched by the Advanced Research Projects Agency for Health (ARPA-H).

• share
• favorite_border

The University of Texas MD Anderson Cancer Center’s Research Highlights provides a glimpse into recent basic, translational and clinical cancer research from MD Anderson experts.

• share
• favorite_border

CRI is co-hosting CICON24 to illuminate pioneering advances in cancer immunotherapy research starting September 8 in National Harbor, MD.

• share
• favorite_border

New findings from a global team of expert scientists in academia and industry has generated world-first research quality standards that will help slash costs and reduce the time it takes to develop advanced nanomedicine treatments and make them available for patients.

• share
• favorite_border

• share
• favorite_border

Back to school, cooler weather, a whiff of pumpkin spice in the air. Yes, it’s flu shot time.

• share
• favorite_border

• share
• favorite_border

• share
• favorite_border

• share
• favorite_border

The FDA has given the greenlight to Pfizer and Moderna for updated Covid-19 vaccines for the fall. ...

• share
• favorite_border

A new study that examined health data on 18 million people reveals higher incidence of mental illnesses for up to a year following severe COVID-19 in unvaccinated people.

• share
• favorite_border

The annual influenza vaccination provides updated protection against the virus but could be improved as there is large variability in its efficacy.

• share
• favorite_border

• share
• favorite_border

A unique influenza vaccine candidate that’s inhaled and based on technology developed by University of Wisconsin–Madison researchers is safe and could bolster protection against seasonal and pandemic influenza for people vulnerable to severe disease when they receive it in addition to the annual flu shot.Those are the results of a randomized, controlled trial of the vaccine candidate, administered in nasal spray form in conjunction with the annual shot to a group of 65- to 85-year-olds in 2022.

• share
• favorite_border

People with multiple sclerosis (MS) have an increased risk of severe coronavirus infection, but there has been concern regarding potential relapse after vaccination. A new study finds that people with MS may not have a higher risk of relapse after COVID-19 vaccination. The study is published in the August 14, 2024, online issue of Neurology®, the medical journal of the American Academy of Neurology.